Photo courtesy Hill's Pet Nutrition While some signs of aging in dogs and cats are obvious, brain health remains one of the more elusive aspects of veterinary care. Signs of early cognitive decline are often mistaken by pet parents as normal parts of aging, while other health challenges may present with more acute symptoms, leading to cognitive decline being missed or deprioritized in a treatment plan. As research continues to reveal more about aging pets and evidence of concurrent conditions in elderly pets grows, the case for multimodal treatment, including nutrition, is stronger than ever. Below are answers to some questions that could help us get into the minds of our geriatric patients and deliver better care. What happens to pets’ brains as they grow older? As pets age, their brains undergo profound physical and chemical changes that fundamentally affect their thinking, memory, and behavior. The core process in the aging pet brain is neurodegeneration, which closely mirrors Alzheimer’s disease (AD) pathology through the hallmark deposition of toxic amyloid-beta (Aβ) plaques and—particularly in cats—neurofibrillary tangles. These tangles are made up of clumps of tau protein that accumulate in neurons. In healthy neurons, tau proteins help stabilize neuronal microtubules, but in diseases such as AD and in aging cats, the tau protein becomes hyperphosphorylated and forms tangles, disrupting normal cell function. These proteinopathies initiate a cascade involving chronic cellular stress and dysfunction. Specifically, there is mitochondrial dysfunction, leading to energy deficits (hypometabolism) and increased oxidative stress in neurons critical for cognitive function. This damage is exacerbated by persistent neuroinflammation (gliosis), in which activated microglia and astrocytes release cytotoxic cytokines, thereby accelerating neuronal death. Ultimately, these biological insults cause widespread synaptic loss, gross structural changes such as cerebral atrophy—especially in the cortex and hippocampus—and depletion of key neurotransmitters like acetylcholine. These cumulative deficits manifest clinically as confusion, memory loss, and altered behaviors characteristic of cognitive dysfunction syndrome (CDS). Why is cognitive decline in dogs and cats often undiagnosed? The frequent underdiagnosis of CDS in dogs and cats stems primarily from the pet parent’s normalization of clinical signs. Subtle changes, such as disorientation or altered sleep cycles, are often mistakenly attributed to inevitable “old age” rather than neurodegenerative pathology. This can prevent timely veterinary consultation, allowing the condition to progress significantly before it is detected. Further compounding the issue, a definitive CDS diagnosis is one of exclusion. A critical technical limitation is the current absence of reliable, non-invasive ante-mortem diagnostic biomarkers (e.g., specific protein assays for Aβ or tau) in clinical practice. Consequently, diagnosis relies heavily on subjective pet parent questionnaires, which can suffer from reporting bias and lack the sensitivity to detect early-stage cognitive impairment. This reliance on exclusionary criteria and subjective assessments, combined with some common misconceptions about aging, results in a substantial disparity between the high estimated prevalence of CDS and the low rate of formal diagnosis. Photo courtesy Hill's Pet Nutrition How are cognition and other age-related challenges intertwined? The high interdependency between cognition and other age-related challenges in senior pets can establish a cycle of decline that can result in changes to the pet’s quality of life. The chronic presence of pain, from osteoarthritis (OA), for example, can act as a profound stressor, driving systemic inflammation that accelerates neurodegeneration.1 This peripheral inflammation introduces circulating pro-inflammatory cytokines into the brain, directly exacerbating the core pathology of CDS. Conversely, cognitive impairment itself can actively worsen physical conditions; for example, a disoriented pet may forget the location of resources or be unable to navigate its environment effectively. Further, limited mobility leads to a sedentary lifestyle, reducing the environmental enrichment necessary to maintain synaptic plasticity and brain health. Sensory deficits frequently cause confusion and anxiety, mimicking or amplifying the behavioral signs of CDS. Therefore, effectively managing age-related issues such as pain and immobility is not merely supportive care but a critical intervention to slow the progression of cognitive decline and improve overall well-being for pets as they age. What learnings from human research around cognitive decline can help us better understand pet cognition? Learning from research on human cognitive decline significantly advances our understanding of pet cognition, largely due to the striking pathophysiological similarities observed across species. The identification of Aβ plaques and tau protein tangles as key hallmarks in human AD prompted researchers to confirm these identical proteinopathies in the brains of dogs and cats with CDS. This shared pathology enables the direct translation of human research on the roles of neuroinflammation (microglial activation) and oxidative stress as central drivers of neurodegeneration in pets. Consequently, many therapeutic and nutritional interventions proven to modulate these mechanisms in human trials—such as the use of antioxidants, omega-3 fatty acids (EPA and DHA), and medium-chain triglycerides (MCTs)—have been translated into veterinary medicine to support cognitive health. The use of advanced human neuroimaging techniques like MRI and FDG-PET scans has also confirmed similar patterns of cerebral atrophy and hypometabolism in the brains of pets with CDS. This translational approach further leverages dogs and cats as relevant, spontaneous models for AD drug discovery, benefiting both human and animal health outcomes. What role does nutrition play in supporting cognitive function in pets? Longitudinal studies have shown the positive impact of foods fortified with antioxidants, mitochondrial cofactors, and omega-3 fatty acids on age-related cognitive decline in dogs.2 Similarly, ingredients like omega-3 fatty acids have been shown to reduce inflammation, which can help support dogs with degenerative joint disease (DJD), another age-related concern in canines.2 New innovations in pet nutrition3 can support the management of complex cases where concurrent conditions need to be addressed, a scenario more common than not in an older pet population. Chelsie Estey, MSc, DVM, DACVIM (Neurology), is the U.S. chief veterinary officer at Hill’s Pet Nutrition. References Wrightson, R., Albertini, M., et. Al. (2023). The Relationship between Signs of Medical Conditions and Cognitive Decline in Senior Dogs. Animals. https://www.mdpi.com/2076-2615/13/13/2203 Hill’s Pet Nutrition (2024). Complete and Balanced Food Tailored for Senior Dogs Helps Manage Age-Related Cognitive Decline and Improves Mobility to Enhance the Lives of Senior Dogs. Data on file. Hill’s Pet Nutrition. Managing Concurrent Conditions in Senior Pets. Hill’s Veterinary Professional Resource Center. https://www.hillsvet.com/pet-nutrition/concurrent-conditions